Syncona Limited

Syncona, founded by the Wellcome Trust in 2012 and listed on the London Stock Exchange (FTSE 250), is a leading life science investor that creates, builds and scales a portfolio of global leaders in life science. Its Investment Manager, Syncona Investment Management Limited (SIML), works in close partnership with world-class academic founders and experienced management teams to develop transformational treatments for patients, with a focus on cell therapy, gene therapy, small molecules and biologics. The firm takes a long-term view, underpinned by a strategic capital base that enables it to maintain significant ownership positions and provide control and flexibility over portfolio management. Syncona's NAV Growth Framework focuses on funding portfolio companies to key value inflection points that can drive significant NAV growth through M&A and liquidity events. The firm targets a diversified portfolio of 20–25 companies across pre-clinical, clinical, late-stage clinical and commercial stages, with an ambition to deliver 3–5 companies to late-stage development where it holds significant ownership positions. As CEO Chris Hollowood has stated: "The fundamentals for investing in healthcare remain strong and wherever there is innovation, there is opportunity for investors."